source
- FDA approves Nuvalent lung cancer drug shortly after GSK completes $10.6 billion acquisitionThe FDA announced Wednesday that it has approved a lung cancer medicine from Nuvalent, marking a key regulatory milestone for the biotech. The clearance arrived just a week after GlaxoSmithKline c…
- AstraZeneca’s rare disease drug Wainua fails Phase 3, narrowing path to $80 billion sales goalAstraZeneca announced that its rare disease therapy Wainua did not meet its primary endpoints in a Phase 3 trial, ending plans to broaden the drug’s label for transthyretin amyloidosis cardiomyopat…